The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Emtricitabine/Tenofovir disoproxil Clonmel 200 mg/245 mg film-coated tablets

200 mg/245 milligram(s) Film-coated tablet

Clonmel Healthcare LtdPA0126/289/001

Main Information

Trade NameEmtricitabine/Tenofovir disoproxil Clonmel 200 mg/245 mg film-coated tablets
Active SubstancesEmtricitabine
Tenofovir disoproxil
Strength200 mg/245 milligram(s)
Dosage FormFilm-coated tablet
Licence HolderClonmel Healthcare Ltd
Licence NumberPA0126/289/001

Group Information

ATC CodeJ05AR Antivirals for treatment of HIV infections, combinations
J05AR03 tenofovir disoproxil and emtricitabine

Status

Authorised/WithdrawnAuthorised
Licence Issued26/08/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Educational Materials - Patient

Generics Information

Interchangeable List CodeIC0107-165-003
Interchangeable List DocumentPDF of Interchangeable List
« Back